Previous Close | 44.37 |
Open | 44.22 |
Bid | 44.30 x 100 |
Ask | 44.36 x 100 |
Day's Range | 43.19 - 44.56 |
52 Week Range | 41.15 - 71.22 |
Volume | 399,625 |
Avg. Volume | 1,318,370 |
Market Cap | 6.847B |
Beta | 2.41 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.03 |
Earnings Date | Apr 26, 2018 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 55.45 |
Jim Cramer shares his take on callers' favorite stocks at lightning speed, including a newly public streaming play.
The FDA is changing its mind on ALKS-5461.
We discuss the pros and cons for J&J’s latest quarterly results, plus Alkermes gets a do-over and Celldex flops.
DUBLIN , April 19, 2018 /PRNewswire/ -- Alkermes plc (NASDAQ: ALKS) will host a conference call and webcast presentation at 8:30 a.m. ET ( 1:30 p.m. BST ) on Thursday, Apr. 26, 2018 , to discuss the company's ...
The biotech space was a witness to a series of events. while share price of several stocks moved up, a few fell substantially.
LONDON, UK / ACCESSWIRE / April 18, 2018 / Active-Investors.com has just released a free research report on Alkermes PLC (NASDAQ: ALKS). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ALKS as the Company's latest news hit the wire. On April 16, 2018, the Company announced that the US Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for ALKS 5461 for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressant therapies.
Shares of Alkermes (ALKS) rose when the FDA accepted for review the new drug application for its depression candidate ALKS 5461 two weeks after it had issued a Refusal to File letter.
Jim Cramer shares his take on callers' favorite stocks at lightning speed, including a newly public streaming play.
Two weeks ago, the agency told Alkermes it needed more trials for antidepressant drug candidate ALKS-5461. The agency, however, had a change of heart, sending shares jumping on the news.
Shares of Alkermes PLC soared 21% in premarket trade Monday, after the biopharmaceutical company said the Food and Drug Administration accepted for review the company's new drug application (NDA) for its ...
DUBLIN, April 16, 2018 /PRNewswire/ -- Alkermes plc (ALKS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for ALKS 5461, a novel, once-daily, oral investigational medicine for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressant therapies. FDA's target action date for the ALKS 5461 NDA is Jan. 31, 2019.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
Following a recent setback, management has a tougher road ahead.
NEW YORK, April 10, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
Takeda may make an offer to buy Shire, but it might prove costly. Also, the FDA slaps Alkermes with a dreaded Refusal to File letter.
The FDA's refusal to review Alkermes' depression candidate AKLS 5461 has brought depression disease market in focus. Here we take a look at a few companies developing products for this market.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
A stumble at Alkermes could mean one less competitor for a new drug making its way through J&J's pipeline.
The biotech sector grabbed headlines last week as Edge Therapeutics crashed on news of discontinuation of its phase III study while Amgen's Blincyto got FDA's nod for label expansion.
Alkermes (ALKS) shares declined by more than 21% as it received a Refusal to File letter from the FDA for its pipeline candidate, ALKS 5461, which was developed for major depressive disorder (MDD).
Levi & Korsinsky announces it has commenced an investigation of Alkermes plc concerning possible violations of federal securities laws.